120 related articles for article (PubMed ID: 15585451)
41. Clinical importance of Stenotrophomonas maltophilia nosocomial pneumonia due to its high mortality in hemodialysis patients.
Wakino S; Imai E; Yoshioka K; Kamayachi T; Minakuchi H; Hayashi K; Inamoto H; Itoh H
Ther Apher Dial; 2009 Jun; 13(3):193-8. PubMed ID: 19527465
[TBL] [Abstract][Full Text] [Related]
42. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
[TBL] [Abstract][Full Text] [Related]
43. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
Goethaert K; Van Looveren M; Lammens C; Jansens H; Baraniak A; Gniadkowski M; Van Herck K; Jorens PG; Demey HE; Ieven M; Bossaert L; Goossens H
Clin Microbiol Infect; 2006 Jan; 12(1):56-62. PubMed ID: 16460547
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of pneumonia in hospitalized patients--results of a multicenter study using a fourth-generation cephalosporin (cefepime)].
de Medeiros EA
Rev Assoc Med Bras (1992); 1999; 45(1):2-8. PubMed ID: 10436586
[TBL] [Abstract][Full Text] [Related]
45. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
46. Determination of the frequency of inadequate antibiotic therapy using calculation of indication failure (IF), cumulative indication failure (CIF), and balanced indication failure (BIF).
Burgmann H
Wien Med Wochenschr; 2003; 153(7-8):163-5. PubMed ID: 12764870
[TBL] [Abstract][Full Text] [Related]
47. [Ventilator-associated pneumonia and multiresistant bacteria].
Heininger A; Unertl K
Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Feb; 42(2):122-9. PubMed ID: 17309020
[TBL] [Abstract][Full Text] [Related]
48. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
49. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Tennenberg AM; Davis NB; Wu SC; Kahn J
Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
[TBL] [Abstract][Full Text] [Related]
50. [Rational use of antibiotics in hospitals].
Berild D; Haug JB
Tidsskr Nor Laegeforen; 2008 Oct; 128(20):2335-9. PubMed ID: 19096490
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
52. What is healthcare-associated pneumonia, and how should it be treated?
Craven DE
Curr Opin Infect Dis; 2006 Apr; 19(2):153-60. PubMed ID: 16514340
[TBL] [Abstract][Full Text] [Related]
53. Doripenem: a new carbapenem in the treatment of nosocomial infection.
Mandell L
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S1-3. PubMed ID: 19619016
[TBL] [Abstract][Full Text] [Related]
54. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations.
Wagenlehner FM; Weidner W; Naber KG
J Hosp Infect; 2005 Jul; 60(3):191-200. PubMed ID: 15893853
[TBL] [Abstract][Full Text] [Related]
55. The selection of microorganisms for treatment with broad-spectrum cephalosporins.
Knothe H
Br J Clin Pract Suppl; 1988 Feb; 57():46-8. PubMed ID: 3140876
[No Abstract] [Full Text] [Related]
56. Antibiotic resistance in hospital infections: the role of newer cephalosporins.
Negri MC; Morosini MI; Blázquez J; Baquero F
Clin Microbiol Infect; 2000; 6 Suppl 3():95-7. PubMed ID: 11449667
[No Abstract] [Full Text] [Related]
57. [The use of cefepime for treating patients with severe hospital infections].
Iakovlev VP
Antibiot Khimioter; 1999; 44(11):37-43. PubMed ID: 10629741
[No Abstract] [Full Text] [Related]
58. Study of cefotaxime twice daily for the therapy of postoperative pneumonia. The German Cefotaxime Study Group.
Bruch HP; Kujath P
Diagn Microbiol Infect Dis; 1995; 22(1-2):203-7. PubMed ID: 7587041
[TBL] [Abstract][Full Text] [Related]
59. [Study of cefepime in Russia].
Iakovlev VP; Iakovlev SV
Antibiot Khimioter; 2004; 49(10):30-8. PubMed ID: 15850056
[No Abstract] [Full Text] [Related]
60. [Fourth generation cephalosporins in treating severe hospital infections: pharmacoeconomic aspects].
Rudakova AV
Antibiot Khimioter; 2001; 46(9):33-9. PubMed ID: 11871014
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
